Current Environment: Production

Warning

An important message to our patients and their caregivers.

We are here for you. Read more

Summary

Investigate the inhibitor development rate of Human cl rhFVIII in previously untreated patients with severe Hemophilia A.

Conditions

Severe Hemophilia A

Recruitment Status

COMPLETED

Eligibility Criteria

Inclusion Criteria:

* Male patients
* Severe Hemophilia A (FVIII:C \<1%)
* No previous treatment with FVIII concentrates or other blood products containing FVIII

Exclusion Criteria:

* Diagnosis with a coagulation disorder other than Hemophilia A
* Severe liver or kidney disease
* Concomitant treatment with any systemic immunosuppressive drug

Intervention

Intervention Type

Intervention Name

BIOLOGICAL

Human cl rhFVIII

Phase

PHASE3

Gender

MALE

Min Age

N/A

Max Age

N/A

Download Date

2021-01-19

Principal Investigator

N/A

Primary Contact Information

For more information on this trial, visit clinicaltrials.gov.

Contact

For more information and to contact the study team:

Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients NCT01712438